Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Payables (2016 - 2025)

Cytokinetics (CYTK) has disclosed Payables for 16 consecutive years, with $22.3 million as the latest value for Q4 2025.

  • Quarterly Payables changed N/A to $22.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $22.3 million for FY2025, N/A changed from the prior year.
  • Payables for Q4 2025 was $22.3 million at Cytokinetics, up from $22.1 million in the prior quarter.
  • The five-year high for Payables was $25.6 million in Q4 2022, with the low at $7.8 million in Q1 2021.
  • Average Payables over 5 years is $16.2 million, with a median of $14.9 million recorded in 2021.
  • The sharpest move saw Payables skyrocketed 161.95% in 2021, then dropped 25.29% in 2024.
  • Over 5 years, Payables stood at $21.1 million in 2021, then increased by 21.45% to $25.6 million in 2022, then dropped by 16.02% to $21.5 million in 2023, then plummeted by 46.15% to $11.6 million in 2024, then surged by 92.88% to $22.3 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $22.3 million, $22.1 million, and $16.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.